Screener / SEC EDGAR /CIK 0000883984 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

ICU Medical Inc ICUI

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What ICUI's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

In addition to the above special items, Adjusted EBITDA additionally excludes the following items from net income: release Nov 5, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

ICU Medical Announces Third Quarter 2026 Results

Open on SEC

and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026.

Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP gross profit for the third quarter of 2026 was $234.8 million, as compared to $200.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2026 was 42%, as compared to 37% in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. Adjusted diluted earnings per share for the third quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025. Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to $105.9 million for the third quarter of 2025.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."

Revenues by product line for the three and nine months ended September 30, 2026 and 2025 were as follows (in millions):

*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. The nine months ended September 30, 2025 includes $127.4 million of revenue, including contract manufacturing revenue, primarily related to the IV Solutions disposed business. Additionally, Vital Care includes contract manufacturing revenue, related primarily to our joint venture, of $4.2 million and $12.5 million for the three and nine months ended September 30, 2026, respectively, as compared to $3.6 million and $7.1 million of contract manufacturing revenue for the three and nine months ended September 30, 2025, respectively.

** Totals may differ from the income statement due to the rounding of product lines.

The Company Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range

The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of the guidance range. The Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00.

The Company will host a conference call to discuss its third quarter financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 245-3047, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as

“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2026. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions, including from escalated conflicts in the Middle East and associated disruptions to shipping and increased oil costs; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical integration; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS CURRENT ASSETS: Cash and cash $ 301,780 $ 307,963 equivalents Accounts receivable, net of allowance 206,258 180,515 for doubtful accounts Inventories 607,268 615,859 Prepaid expenses and other current 104,559 86,217 assets TOTAL CURRENT 1,219,865 1,190,554 ASSETS PROPERTY, PLANT AND EQUIPMENT, 444,991 451,817 net OPERATING LEASE RIGHT-OF-USE 36,170 54,470 ASSETS GOODWILL 1,482,783 1,499,754 INTANGIBLE 536,466 633,559 ASSETS, net DEFERRED INCOME 25,437 25,891 TAXES OTHER ASSETS 69,161 62,877 INVESTMENTS IN UNCONSOLIDATED 128,929 131,586 AFFILIATES TOTAL ASSETS $ 3,943,802 $ 4,050,508 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 142,989 $ 154,374 Accrued 342,805 315,337 liabilities Current portion 18,750 18,750 of long-term debt Income tax 10,089 10,400 payable TOTAL CURRENT 514,633 498,861 LIABILITIES LONG-TERM DEBT 1,133,096 1,265,917 OTHER LONG-TERM 68,969 89,536 LIABILITIES DEFERRED INCOME 8,764 37,756 TAXES INCOME TAX 26,922 34,613 LIABILITY COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY: Convertible preferred stock, $1.00 par value; Authorized — — — 500 shares; Issued and outstanding — none Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —25,186 and 24,688 shares at September 30, 2026 and December 31, 2,519 2,469 2025, respectively, and outstanding — 25,010 and 24,688 shares at September 30, 2026 and December 31, 2025, respectively Additional 1,487,156 1,465,118 paid-in capital Treasury stock, -23,040 -22 at cost Retained earnings 766,956 690,890 Accumulated other comprehensive -42,173 -34,630 loss TOTAL STOCKHOLDERS' 2,191,418 2,123,825 EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' $ 3,943,802 $ 4,050,508 EQUITY

Nine months ended CASH FLOWS FROM OPERATING September 30, ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 76,066 $ 16,466 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 149,234 149,912 amortization Noncash lease expense 11,341 13,739 Stock compensation 37,744 41,879 Loss on disposal and write-off of property, plant and 2,074 3,211 equipment and other assets Debt issuance costs 2,398 5,112 amortization Undistributed equity in earnings of -266 -1,296 unconsolidated affiliates Net gain on sale of -2,240 -44,792 business Other 20,473 18,217 Changes in operating assets and liabilities, net of amounts acquired:

Accounts receivable -29,548 3,943 Inventories 2,319 -36,213 Prepaid expenses and other current -8,711 -4,721 assets Other assets -1,737 -7,149 Accounts payable -10,685 23,328 Accrued liabilities 12,770 -28,887 Income taxes, including excess tax -42,587 -33,501 benefits and deferred income taxes Net cash provided by operating 218,645 119,248 activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and -45,999 -63,397 equipment Proceeds from sale of 5,931 211,185 business Proceeds from sale of 39 42 assets Intangible asset additions -5,245 -7,210 Net cash (used in) provided by investing -45,274 140,620 activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal repayments of -134,688 -272,750 long-term debt Proceeds from exercise of 490 5,972 stock options Payments on finance leases -1,966 -1,543 Tax withholding payments related to net -39,166 -8,719 share settlement of equity awards Net cash used in financing -175,330 -277,040 activities Effect of exchange rate -4,224 8,338 changes on cash NET DECREASE IN CASH AND CASH -6,183 -8,834 EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of 307,963 308,566 period CASH AND CASH EQUIVALENTS, $ 301,780 $ 299,732 end of period

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non- GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation.

The non-GAAP financial measures as shown in the tables below, exclude special items because they are highly variable or unusual and impact year-over-year comparisons.

For the three months ended September 30, 2026 and 2025, special items include the following:

Contract manufacturing : We manufacture certain products or product components in accordance with manufacturing services agreements. We do not include the contract revenue in our adjusted revenue, or any gross profit impact in our adjusted gross profit as the commercial relationship under these types of agreements are originally negotiated contemporaneously with a business combination or other transactions and are not indicative of normal market transactions.

Stock compensation expense : Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock- based compensation in order to better understand our operating performance.

Intangible asset amortization expense : We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.

Restructuring, strategic transaction and integration : We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Settlements : Occasionally, we are involved in contract renegotiations or other events that may result in one-time settlements. We exclude these settlements as they have no direct correlation to the operation of our ongoing business.

Quality system and product-related remediation : We exclude certain quality system and product-related remediation charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Noncash release of loss on contract provision : We provide certain services under fixed priced arrangements in accordance with a transition services arrangement. We do not include the loss on contract provision or subsequent release net of the related interest accretion as a result of providing those services in our non-GAAP financial measures as the agreement was negotiated contemporaneously with a disposition and is not indicative of a normal market transaction. The loss provision and subsequent release is a non-recurring noncash adjustment that if included may limit the comparability of our ongoing operations with prior and future periods.

Gain on sale of business : We exclude any non-cash gains/losses on the sale of a business in determining our non-GAAP financial measures as the inclusion may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Impairment of equity method investment: We exclude impairment losses on equity method investments in determining our non-GAAP financial measures as they do not reflect the core, recurring operational performance of the business and may limit the

comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Tariff Refunds : We exclude certain IEEPA tariff refunds in determining our non- GAAP financial measures because these regulatory adjustments are infrequent, non-operational items that may limit the comparability of our ongoing operations with prior and future periods.

Noncash impairment and other JV items: We exclude our proportionate share of noncash impairment charges, accelerated depreciation, restructuring costs and other items recorded by our equity method investment joint ventures. We also exclude certain items that, based on our contractual relationship with our joint venture partner, are fully the responsibility of or for the benefit of our joint venture partner. We eliminate these items in determining our non-GAAP financial measures because they do not reflect the core, recurring operational performance of the underlying joint ventures and their inclusion would limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is not representative of our ordinary course operations and consistent with the goal of providing useful information to investors and management.

In addition to the above special items, Adjusted EBITDA additionally excludes the following items from net income:

Depreciation expense : We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.

Interest, net : We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt.

Taxes : We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items listed above. The tax effect on the special items is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded. Additionally, adjusted diluted EPS may exclude the income tax impact of certain non-recurring discrete tax items that are not reflective of income tax expense/benefit incurred as a result of current period earnings/ loss, as well as the impact of certain deferred tax valuation allowances when assessed against non-GAAP profitability.

We also present Free cash flow as a non-GAAP financial measure as management believes that this is an important measure for use in evaluating overall company financial performance as it measures our ability to generate additional cash flow from business operations. Free cash flow should be considered in addition to, rather than as a substitute for, net income as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. Additionally, our definition of free cash flow is limited and does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as supplemental to our entire statement of cash flows.

We also present organic revenue growth as a non-GAAP financial measure as management believes that this measure provides a more representative view of the Company's underlying growth trajectory by excluding the impact of revenue from non-arm's length transactions, the impact of foreign currency and the revenue associated with acquisitions and divestitures. We calculate constant currency revenue by translating current period foreign currency revenue at prior period comparable exchange rates and we calculate the constant currency growth percentages by dividing the current period constant currency revenue by the prior year comparable period revenue.

The following tables reconcile our non-GAAP financial measures for the periods presented:

Adjusted EBITDA Three months ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── GAAP net income (loss) $ 26,847 $ -3,396 Non-GAAP adjustments: Interest, net 15,240 19,808 Stock compensation 11,863 15,243 expense Depreciation and 49,594 50,802 amortization expense Restructuring, strategic transaction and 6,271 13,138 integration Settlements 1,130 1,426 Quality system and product-related 6,610 13,797 remediation Gain on sale of business -2,240 -2,969 Impairment of equity 2,832 — method investment Noncash release of loss on contract -1,120 -1,076 provision Gross profit on contract -719 -204 manufacturing Tariff refunds -10,358 — Noncash impairment and 766 — other JV items Provision for income 7,193 -658 taxes Total non-GAAP 87,062 109,307 adjustments Adjusted EBITDA $ 113,909 $ 105,911

(In thousands, except percentages and per share data) The Company’s U.S. GAAP results for the three months ended September 30, 2026 included special items which impacted the U.S. GAAP measures as follows:

* The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets, as well as, the tax benefit on the release of income tax reserves in foreign jurisdictions for tax years which are no longer subject to an assessment from the local taxing authorities. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September30, 2026. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non- GAAP annual effective tax rate. Tax reserves were released as a result of the expiration of statute of limitations which resulted in a discrete tax benefit for GAAP purposes. This tax benefit is excluded from our non-GAAP annual effective tax rate to the extent it is not related to on-going business operations.

(In thousands, except percentages and per share data) The Company’s U.S. GAAP results for the three months ended September 30, 2025 included special items which impacted the U.S. GAAP measures as follows:

* The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September 30, 2025. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non-GAAP annual effective tax rate.

(1) We manufacture certain products or product components in accordance with manufacturing services agreements. We do not include the contract revenue in our adjusted

revenue as the commercial relationship under these types of agreements are originally negotiated contemporaneously with a business combination or other transactions and

(2) For businesses divested, non-GAAP organic revenue growth excludes prior period revenue associated with the divested business for the same length

of time they were not owned by the company in the current year. The divested business prior period revenue in this line item does not include MSA revenue, which is excluded on a separate line.

(3) We exclude the impact of foreign exchange rate changes to show a constant currency comparison of our underlying business performance.

Net Debt Net Leverage As of September 30, Ratio Calculation 2026 ────────────────────────────────────────────────────────────────────────────── Current portion $ 18,750 of long-term debt Long-Term Debt 1,133,096 Total GAAP 1,151,846 Long-Term Debt Add: Unamortized Debt Issuance 7,967 Costs/Discounts(… Less: Cash and -301,780 cash equivalents Net Debt $ 858,033 (Non-GAAP) (1)Represents unamortized debt issuance costs and original issue discounts deducted from the carrying value of long-term debt on the Condensed Consolidated Balance Sheets in accordance with U.S. GAAP. Management adds back these costs to present total contractual principal obligations outstanding when evaluating debt leverage. TTM Adjusted EBITDA As of September 30, 2026 GAAP net income $ 60,332 Non-GAAP adjustments: Interest, net 68,124 Stock compensation 51,623 expense Depreciation and amortization 200,065 expense Restructuring, strategic 64,826 transaction and integration Settlements 1,300 Quality system and 30,883 product-related remediation Asset write-offs and similar 887 charges Gain on sale of -2,240 business Impairment of equity method 2,832 investment Noncash release of loss on -4,436 contract provision Gross profit on contract -1,807 manufacturing Tariff refunds -29,246 Noncash impairment and 766 other JV items Provision for -23,104 income taxes Total non-GAAP 360,473 adjustments TTM Adjusted $ 420,805 EBITDA Net Leverage Ratio Net Debt $ 858,033 Divided by: TTM $ 420,805 Adjusted EBITDA Net Leverage 2.04 x Ratio

Low End of High End of Guidance Guidance ────────────────────────────────────────────────────────────────────────────── GAAP net income $ 73 $ 83 Non-GAAP adjustments: Interest, net 65 65 Stock compensation 50 50 expense Depreciation and amortization 203 203 expense Restructuring, strategic 52 52 transaction and integration Quality and regulatory 25 25 initiatives and remediation Noncash release of loss on -4 -4 contract provision Gross profit on contract -2 -2 manufacturing Tariff refunds -19 -19 Benefit for -28 -18 income taxes Total non-GAAP $ 342 $ 352 adjustments Adjusted EBITDA $ 415 $ 435 GAAP income per $ 2.89 $ 3.29 share Non-GAAP adjustments: Stock compensation 1.98 1.98 expense Amortization 5.28 5.28 expense Restructuring, strategic 2.06 2.06 transaction and integration Quality and regulatory 0.99 0.99 initiatives and remediation Noncash release of loss on -0.12 -0.12 contract provision Gross profit on contract -0.08 -0.08 manufacturing Tariff refunds -0.79 -0.79 Tax benefit from discrete reserve release and -1.33 -1.33 valuation allowance Estimated income tax impact from -2.28 -2.28 adjustments Adjusted earnings per $ 8.60 $ 9.00 share

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                ICU Medical Announces Third Quarter 2026 Results                
                                                                                
 and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of  
                                     Range                                      
SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc.
(Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative
medical products, today announced financial results for the quarterly period
ended September 30, 2026.
                                                                                
  Third Quarter 2026 Results                                                    
                                                                                
Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0
million in the same period in the prior year. GAAP gross profit for the third
quarter of 2026 was $234.8 million, as compared to $200.9 million in the same
period in the prior year. GAAP gross margin for the third quarter of 2026 was
42%, as compared to 37% in the same period in the prior year. GAAP net income
for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as
compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for
the third quarter of 2025. Adjusted diluted earnings per share for the third
quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025.
Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to
$105.9 million for the third quarter of 2025.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated
and presented on the basis of methodologies other than in accordance with GAAP.
Please refer to the Use of Non-GAAP Financial Information following the
financial statements herein for further discussion and reconciliations of these
measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results
were ahead of our expectations for Infusion Systems and generally in line with
expectations for the remainder of the business."

Revenues by product line for the three and nine months ended September 30, 2026
and 2025 were as follows (in millions):
                                                                                
       T…                                  N…                                   
       m…                                  m…                                   
       e…                                  e…                                   
       S…                                  S…                                   
  …    3…                      $           3…                        $          
  …    2…          2…          C…          2…           2…           C…         
 ────────────────────────────────────────────────────────────────────────────── 
  …    $     2…    $     2…    $     1…    $     86…    $     82…    $     41…  
  …          1…          1…          1…          56…          50…          53…  
  …                                                                             
  …          6…          7…          -…          21…          35…          -1…  
  …                                                                             
  …    $     5…    $     5…    $     2…    $     1,…    $     1,…    $     -4…  
                                                                                
*On May 1, 2025, we disposed of our IV Solutions business which was included
within our Vital Care product line. The nine months ended September 30, 2025
includes $127.4 million of revenue, including contract manufacturing revenue,
primarily related to the IV Solutions disposed business. Additionally, Vital
Care includes contract manufacturing revenue, related primarily to our joint
venture, of $4.2 million and $12.5 million for the three and nine months ended
September 30, 2026, respectively, as compared to $3.6 million and $7.1 million
of contract manufacturing revenue for the three and nine months ended September
30, 2025, respectively.

** Totals may differ from the income statement due to the rounding of product
lines.

The Company Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High
End of Range

The Company is reaffirming its full year 2026 guidance but expects to end the
fiscal year towards the higher end of the guidance range. The Company's
previously provided full year GAAP net income remains estimated to be in the
range of $73 million to $83 million and GAAP diluted earnings per share to be in
the range of $2.89 to $3.29. The Company's previously provided full year 2026
guidance of Adjusted EBITDA remains estimated to be in the range of $415 million
to $435 million and adjusted diluted earnings per share to be in the range of
$8.60 to $9.00.
                                                                                
  Conference Call                                                               
                                                                                
The Company will host a conference call to discuss its third quarter financial
results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800)
245-3047, conference ID "ICUMED". The conference call will be simultaneously
available by webcast, which can be accessed by going to the Company's website at
www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and
clicking on the Webcast icon and following the prompts. The webcast will also be
available by replay.
                                                                                
  About ICU Medical                                                             
                                                                                
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion
consumables and high-value critical care products used in hospital, alternate
site and home care settings. Our team is focused on providing quality,
innovation and value to our clinical customers worldwide. ICU Medical is
headquartered in San Clemente, California. More information about ICU Medical
can be found at www.icumed.com .
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements contain words such
as

“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the
negative thereof or comparable terminology and may include (without limitation)
information regarding the Company's expectations, goals and intentions regarding
the future and financial outlook for 2026. These forward-looking statements are
based on management's current expectations, estimates, forecasts and projections
about the Company and assumptions management believes are reasonable, all of
which are subject to risks and uncertainties that could cause actual results and
events to differ materially from those stated in the forward-looking statements.
These risks and uncertainties include, but are not limited to: risks from doing
business in foreign countries, including related to tariffs and other barriers
to trade; the Company’s ability to compete successfully, including with larger
international companies and established local companies; decreased demand for
the Company's products; costs related to product development; cost volatility or
potential loss of supply of raw materials due to our dependence on single and
limited source third-party suppliers; ability to achieve operating efficiencies;
risks related to significant sales through our distributors; inflation and
foreign currency exchange rates; impacts from global macroeconomic and
geopolitical conditions, including from escalated conflicts in the Middle East
and associated disruptions to shipping and increased oil costs; healthcare costs
and reimbursement levels; disruptions at the FDA and other governmental
agencies; damage at the Company’s manufacturing or supply facilities; risks
associated with the IV Solutions joint venture and the Smiths Medical
integration; risks associated with the timing and resolution of the 2025 warning
letter; risks related to protection of our information technology systems and
compliance with privacy laws and regulations; risks related to our intellectual
property; and the other important factors described under “Risk Factors” in the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025
and our subsequent filings with the SEC. Forward-looking statements contained in
this press release are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise unless
required by law.
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
                                                                                
               CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)                
                                                                                
                                 (In thousands)                                 
                                                                                
                       September 30,                 December 31,               
                       2026                          2025                       
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  CURRENT ASSETS:                                                               
  Cash and cash        $                  301,780    $                 307,963  
  equivalents                                                                   
  Accounts                                                                      
  receivable, net                                                               
  of allowance                            206,258                      180,515  
  for doubtful                                                                  
  accounts                                                                      
  Inventories                             607,268                      615,859  
  Prepaid expenses                                                              
  and other current                       104,559                       86,217  
  assets                                                                        
  TOTAL CURRENT                         1,219,865                    1,190,554  
  ASSETS                                                                        
  PROPERTY, PLANT                                                               
  AND EQUIPMENT,                          444,991                      451,817  
  net                                                                           
  OPERATING LEASE                                                               
  RIGHT-OF-USE                             36,170                       54,470  
  ASSETS                                                                        
  GOODWILL                              1,482,783                    1,499,754  
  INTANGIBLE                              536,466                      633,559  
  ASSETS, net                                                                   
  DEFERRED INCOME                          25,437                       25,891  
  TAXES                                                                         
  OTHER ASSETS                             69,161                       62,877  
  INVESTMENTS IN                                                                
  UNCONSOLIDATED                          128,929                      131,586  
  AFFILIATES                                                                    
  TOTAL ASSETS         $                3,943,802    $               4,050,508  
  LIABILITIES AND                                                               
  STOCKHOLDERS’                                                                 
  EQUITY                                                                        
  CURRENT                                                                       
  LIABILITIES:                                                                  
  Accounts payable     $                  142,989    $                 154,374  
  Accrued                                 342,805                      315,337  
  liabilities                                                                   
  Current portion                          18,750                       18,750  
  of long-term debt                                                             
  Income tax                               10,089                       10,400  
  payable                                                                       
  TOTAL CURRENT                           514,633                      498,861  
  LIABILITIES                                                                   
  LONG-TERM DEBT                        1,133,096                    1,265,917  
  OTHER LONG-TERM                          68,969                       89,536  
  LIABILITIES                                                                   
  DEFERRED INCOME                           8,764                       37,756  
  TAXES                                                                         
  INCOME TAX                               26,922                       34,613  
  LIABILITY                                                                     
  COMMITMENTS AND                                                               
  CONTINGENCIES                                                                 
  STOCKHOLDERS’                                                                 
  EQUITY:                                                                       
  Convertible                                                                   
  preferred stock,                                                              
  $1.00 par                                                                     
  value; Authorized                             —                            —  
  — 500 shares;                                                                 
  Issued                                                                        
  and outstanding —                                                             
  none                                                                          
  Common stock,                                                                 
  $0.10 par value;                                                              
  Authorized —                                                                  
  80,000 shares;                                                                
  Issued                                                                        
  —25,186 and                                                                   
  24,688 shares at                                                              
  September                                                                     
  30, 2026 and                                                                  
  December 31,                              2,519                        2,469  
  2025,                                                                         
  respectively, and                                                             
  outstanding —                                                                 
  25,010                                                                        
  and 24,688 shares                                                             
  at September 30,                                                              
  2026                                                                          
  and December 31,                                                              
  2025,                                                                         
  respectively                                                                  
  Additional                            1,487,156                    1,465,118  
  paid-in capital                                                               
  Treasury stock,                         -23,040                          -22  
  at cost                                                                       
  Retained earnings                       766,956                      690,890  
  Accumulated other                                                             
  comprehensive                           -42,173                      -34,630  
  loss                                                                          
  TOTAL                                                                         
  STOCKHOLDERS'                         2,191,418                    2,123,825  
  EQUITY                                                                        
  TOTAL LIABILITIES                                                             
  AND STOCKHOLDERS'    $                3,943,802    $               4,050,508  
  EQUITY                                                                        
                                                                                
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
                                                                                
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)           
                                                                                
                     (In thousands, except per share data)                      
                                                                                
          Three                              Nine                               
          mont…                              months                             
          ended                              ended                              
          Sept…                              Septe…                             
          30,                                30,                                
          2026              2025             2026               2025            
 ────────────────────────────────────────────────────────────────────────────── 
  TOT…    $        560,…    $       536,…    $         1,64…    $       1,690…  
  REV…                                                                          
  COST                                                                          
  OF               325,…            336,…              966,…            1,071…  
  GOO…                                                                          
  SOLD                                                                          
  GRO…             234,…            200,…              676,…            619,0…  
  PRO…                                                                          
  OPE…                                                                          
  EXP…                                                                          
  Sel…                                                                          
  gen…             154,…            152,…              460,…            469,3…  
  and                                                                           
  adm…                                                                          
  Res…                                                                          
  and              21,7…            21,2…              65,7…            66,409  
  dev…                                                                          
  Res…                                                                          
  str…                                                                          
  tra…             6,271            13,1…              44,3…            46,053  
  and                                                                           
  int…                                                                          
  TOT…                                                                          
  OPE…             182,…            187,…              571,…            581,8…  
  EXP…                                                                          
  INC…                                                                          
  FROM             52,3…            13,7…              105,…            37,194  
  OPE…                                                                          
  INT…                                                                          
  EXP…             -15,…            -19,…              -47,…            -62,3…  
  net                                                                           
  OTH…                                                                          
  (EX…             -3,1…              607              -4,4…               662  
  INC…                                                                          
  net                                                                           
  GAIN                                                                          
  ON                                                                            
  SALE             2,240            2,969              2,240            44,792  
  OF                                                                            
  BUS…                                                                          
  INC…                                                                          
  (LO…                                                                          
  BEF…                                                                          
  INC…                                                                          
  TAX…                                                                          
  AND                                                                           
  EQU…             36,1…            -2,5…              55,3…            20,260  
  IN                                                                            
  (LO…                                                                          
  EAR…                                                                          
  OF                                                                            
  UNC…                                                                          
  AFF…                                                                          
  (PR…                                                                          
  BEN…                                                                          
  FOR              -7,1…              658              20,4…            -5,090  
  INC…                                                                          
  TAX…                                                                          
  NET                                                                           
  INC…                                                                          
  (LO…             28,9…            -1,8…              75,8…            15,170  
  FROM                                                                          
  CON…                                                                          
  COM…                                                                          
  EQU…                                                                          
  IN                                                                            
  (LO…                                                                          
  EAR…             -2,1…            -1,5…                266             1,296  
  OF                                                                            
  UNC…                                                                          
  AFF…                                                                          
  NET                                                                           
  INC…    $        26,8…    $       -3,3…    $         76,0…    $       16,466  
  (LO…                                                                          
  NET                                                                           
  INC…                                                                          
  (LO…                                                                          
  PER                                                                           
  SHA…                                                                          
  Bas…    $         1.07    $       -0.14    $          3.05    $         0.67  
  Dil…    $         1.07    $       -0.14    $          3.02    $         0.66  
  WEI…                                                                          
  AVE…                                                                          
  NUM…                                                                          
  OF                                                                            
  SHA…                                                                          
  Bas…             25,0…            24,6…              24,9…            24,624  
  Dil…             25,1…            24,6…              25,1…            24,783  
                                                                                
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
          CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)           
                                                                                
                                 (In thousands)                                 
                                                                                
                                 Nine months ended                              
  CASH FLOWS FROM OPERATING      September 30,                                  
  ACTIVITIES:                    2026                           2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                     $                    76,066    $       16,466  
  Adjustments to reconcile                                                      
  net income to                                                                 
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                   149,234           149,912  
  amortization                                                                  
  Noncash lease expense                               11,341            13,739  
  Stock compensation                                  37,744            41,879  
  Loss on disposal and                                                          
  write-off of                                                                  
  property, plant and                                  2,074             3,211  
  equipment and other                                                           
  assets                                                                        
  Debt issuance costs                                  2,398             5,112  
  amortization                                                                  
  Undistributed equity in                                                       
  earnings of                                           -266            -1,296  
  unconsolidated affiliates                                                     
  Net gain on sale of                                 -2,240           -44,792  
  business                                                                      
  Other                                               20,473            18,217  
  Changes in operating assets                                                   
  and                                                                           
  liabilities, net of amounts                                                   
  acquired:                                                                     
                                                                                
  Accounts receivable                                -29,548             3,943  
  Inventories                                          2,319           -36,213  
  Prepaid expenses and other                                                    
  current                                             -8,711            -4,721  
  assets                                                                        
  Other assets                                        -1,737            -7,149  
  Accounts payable                                   -10,685            23,328  
  Accrued liabilities                                 12,770           -28,887  
  Income taxes, including                                                       
  excess tax                                         -42,587           -33,501  
  benefits and deferred                                                         
  income taxes                                                                  
  Net cash provided by                                                          
  operating                                          218,645           119,248  
  activities                                                                    
  CASH FLOWS FROM INVESTING                                                     
  ACTIVITIES:                                                                   
  Purchases of property,                                                        
  plant and                                          -45,999           -63,397  
  equipment                                                                     
  Proceeds from sale of                                5,931           211,185  
  business                                                                      
  Proceeds from sale of                                   39                42  
  assets                                                                        
  Intangible asset additions                          -5,245            -7,210  
  Net cash (used in) provided                                                   
  by investing                                       -45,274           140,620  
  activities                                                                    
  CASH FLOWS FROM FINANCING                                                     
  ACTIVITIES:                                                                   
  Principal repayments of                           -134,688          -272,750  
  long-term debt                                                                
  Proceeds from exercise of                              490             5,972  
  stock options                                                                 
  Payments on finance leases                          -1,966            -1,543  
  Tax withholding payments                                                      
  related to net                                     -39,166            -8,719  
  share settlement of equity                                                    
  awards                                                                        
  Net cash used in financing                        -175,330          -277,040  
  activities                                                                    
  Effect of exchange rate                             -4,224             8,338  
  changes on cash                                                               
  NET DECREASE IN CASH AND                                                      
  CASH                                                -6,183            -8,834  
  EQUIVALENTS                                                                   
  CASH AND CASH EQUIVALENTS,                                                    
  beginning of                                       307,963           308,566  
  period                                                                        
  CASH AND CASH EQUIVALENTS,     $                   301,780    $      299,732  
  end of period                                                                 
                                                                                
                                                                                
   Use of Non-GAAP Financial Information                                        
                                                                                
This press release contains financial measures that are not calculated in
accordance with U.S. generally accepted accounting principles ("GAAP"). The non-
GAAP financial measures should be considered supplemental to, and not as a
substitute for, or superior to, financial measures calculated in accordance with
GAAP. There are material limitations in using these non-GAAP financial measures
because they are not prepared in accordance with GAAP and may not be comparable
to similarly titled non-GAAP financial measures used by other companies,
including peer companies. Our management believes that the non-GAAP data
provides useful supplemental information to management and investors regarding
our performance and facilitates a more meaningful comparison of results of
operations between current and prior periods. We use non-GAAP financial measures
in addition to and in conjunction with GAAP financial measures to analyze and
assess the overall performance of our business, in making financial, operating
and planning decisions, and in determining executive incentive compensation.

The non-GAAP financial measures as shown in the tables below, exclude special
items because they are highly variable or unusual and impact year-over-year
comparisons.

For the three months ended September 30, 2026 and 2025, special items include
the following:

Contract manufacturing : We manufacture certain products or product components
in accordance with manufacturing services agreements. We do not include the
contract revenue in our adjusted revenue, or any gross profit impact in our
adjusted gross profit as the commercial relationship under these types of
agreements are originally negotiated contemporaneously with a business
combination or other transactions and are not indicative of normal market
transactions.

Stock compensation expense : Stock-based compensation is generally fixed at the
time the stock-based instrument is granted and amortized over a period of
several years. The value of our restricted stock awards is determined using the
grant date stock price, which may not be indicative of our operational
performance over the expense period. Additionally, in order to establish the
fair value of performance-based stock awards, which are currently an element of
our ongoing stock-based compensation, we are required to apply judgment to
estimate the probability of the extent to which performance objectives will be
achieved. Based on the above factors, we believe it is useful to exclude stock-
based compensation in order to better understand our operating performance.

Intangible asset amortization expense : We do not acquire businesses or
capitalize certain patent costs on a predictable cycle. The amount of purchase
price allocated to intangible assets and the term of amortization can vary
significantly and are unique to each acquisition. Capitalized patent costs can
vary significantly based on our current level of development activities. We
believe that excluding amortization of intangible assets provides the users of
our financial statements with a consistent basis for comparison across
accounting periods.

Restructuring, strategic transaction and integration : We incur restructuring
and strategic transaction charges that result from events, which arise from
unforeseen circumstances and/or often occur outside of the ordinary course of
our ongoing business. Although these events are reflected in our GAAP financial
statements, these unique transactions may limit the comparability of our ongoing
operations with prior and future periods.

Settlements : Occasionally, we are involved in contract renegotiations or other
events that may result in one-time settlements. We exclude these settlements as
they have no direct correlation to the operation of our ongoing business.

Quality system and product-related remediation : We exclude certain quality
system and product-related remediation charges in determining our non-GAAP
financial measures as they may limit the comparability of our ongoing operations
with prior and future periods and distort the evaluation of our normal operating
performance.

Noncash release of loss on contract provision : We provide certain services
under fixed priced arrangements in accordance with a transition services
arrangement. We do not include the loss on contract provision or subsequent
release net of the related interest accretion as a result of providing those
services in our non-GAAP financial measures as the agreement was negotiated
contemporaneously with a disposition and is not indicative of a normal market
transaction. The loss provision and subsequent release is a non-recurring
noncash adjustment that if included may limit the comparability of our ongoing
operations with prior and future periods.

Gain on sale of business : We exclude any non-cash gains/losses on the sale of a
business in determining our non-GAAP financial measures as the inclusion may
limit the comparability of our ongoing operations with prior and future periods
and distort the evaluation of our normal operating performance.

Impairment of equity method investment: We exclude impairment losses on equity
method investments in determining our non-GAAP financial measures as they do not
reflect the core, recurring operational performance of the business and may
limit the

comparability of our ongoing operations with prior and future periods and
distort the evaluation of our normal operating performance.

Tariff Refunds : We exclude certain IEEPA tariff refunds in determining our non-
GAAP financial measures because these regulatory adjustments are infrequent,
non-operational items that may limit the comparability of our ongoing operations
with prior and future periods.

Noncash impairment and other JV items: We exclude our proportionate share of
noncash impairment charges, accelerated depreciation, restructuring costs and
other items recorded by our equity method investment joint ventures. We also
exclude certain items that, based on our contractual relationship with our joint
venture partner, are fully the responsibility of or for the benefit of our joint
venture partner. We eliminate these items in determining our non-GAAP financial
measures because they do not reflect the core, recurring operational performance
of the underlying joint ventures and their inclusion would limit the
comparability of our ongoing operations with prior and future periods and
distort the evaluation of our normal operating performance.

From time to time in the future, there may be other items that we may exclude if
we believe that doing so is not representative of our ordinary course operations
and consistent with the goal of providing useful information to investors and
management.

In addition to the above special items, Adjusted EBITDA additionally excludes
the following items from net income:

Depreciation expense : We exclude depreciation expense in deriving adjusted
EBITDA because companies utilize productive assets of different ages and the
depreciable lives can vary significantly resulting in considerable variability
in depreciation expense among companies.

Interest, net : We exclude interest in deriving adjusted EBITDA as interest can
vary significantly among companies depending on a company's level of income
generating instruments and/or level of debt.

Taxes : We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be
non-core to the business and may limit the comparability of our ongoing
operations with prior and future periods and distort the evaluation of our
normal operating performance.

Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items
listed above. The tax effect on the special items is calculated using the
specific tax rate applied to each adjustment based on the nature of the item/or
the tax jurisdiction in which the item has been recorded. Additionally, adjusted
diluted EPS may exclude the income tax impact of certain non-recurring discrete
tax items that are not reflective of income tax expense/benefit incurred as a
result of current period earnings/ loss, as well as the impact of certain
deferred tax valuation allowances when assessed against non-GAAP profitability.

We also present Free cash flow as a non-GAAP financial measure as management
believes that this is an important measure for use in evaluating overall company
financial performance as it measures our ability to generate additional cash
flow from business operations. Free cash flow should be considered in addition
to, rather than as a substitute for, net income as a measure of our performance
or net cash provided by operating activities as a measure of our liquidity.
Additionally, our definition of free cash flow is limited and does not represent
residual cash flows available for discretionary expenditures due to the fact
that the measure does not deduct the payments required for debt service and
other obligations or payments made for business acquisitions. Therefore, we
believe it is important to view free cash flow as supplemental to our entire
statement of cash flows.

We also present organic revenue growth as a non-GAAP financial measure as
management believes that this measure provides a more representative view of the
Company's underlying growth trajectory by excluding the impact of revenue from
non-arm's length transactions, the impact of foreign currency and the revenue
associated with acquisitions and divestitures. We calculate constant currency
revenue by translating current period foreign currency revenue at prior period
comparable exchange rates and we calculate the constant currency growth
percentages by dividing the current period constant currency revenue by the
prior year comparable period revenue.

The following tables reconcile our non-GAAP financial measures for the periods
presented:
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
       Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)        
                                                                                
                                 (In thousands)                                 
                                                                                
                              Adjusted EBITDA                                   
                              Three months ended                                
                              September 30,                                     
                              2026                             2025             
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP net income (loss)      $                      26,847    $        -3,396  
  Non-GAAP adjustments:                                                         
  Interest, net                                      15,240             19,808  
  Stock compensation                                 11,863             15,243  
  expense                                                                       
  Depreciation and                                   49,594             50,802  
  amortization expense                                                          
  Restructuring, strategic                                                      
  transaction and                                     6,271             13,138  
  integration                                                                   
  Settlements                                         1,130              1,426  
  Quality system and                                                            
  product-related                                     6,610             13,797  
  remediation                                                                   
  Gain on sale of business                           -2,240             -2,969  
  Impairment of equity                                2,832                  —  
  method investment                                                             
  Noncash release of loss                                                       
  on contract                                        -1,120             -1,076  
  provision                                                                     
  Gross profit on contract                             -719               -204  
  manufacturing                                                                 
  Tariff refunds                                    -10,358                  —  
  Noncash impairment and                                766                  —  
  other JV items                                                                
  Provision for income                                7,193               -658  
  taxes                                                                         
  Total non-GAAP                                     87,062            109,307  
  adjustments                                                                   
  Adjusted EBITDA             $                     113,909    $       105,911  
                                                                                
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
       Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)        
                                                                                
             (In thousands, except percentages and per share data)              
The Company’s U.S. GAAP results for the three months ended September 30, 2026
included special items which impacted the U.S. GAAP measures as follows:
                                                                                
                                                                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
______________________

* The Company’s non-GAAP annual effective tax rate is calculated without the tax
expense related to the valuation allowance against certain U.S. Federal and
State deferred tax assets, as well as, the tax benefit on the release of income
tax reserves in foreign jurisdictions for tax years which are no longer subject
to an assessment from the local taxing authorities. The valuation allowance was
recorded based on an assessment of available positive and negative evidence,
including, predominantly, an estimate that we will be in a three-year cumulative
U.S. loss position on a GAAP basis as of September30, 2026. However, based on
the same assessment, including, predominantly, our being, in a three-year
cumulative U.S. income position on a non-GAAP basis, which excludes the impact
of our non-GAAP adjustments, we concluded that recording a valuation allowance
would not have been appropriate for non-GAAP reporting. As a result, the tax
expense for the valuation allowance was added back to our calculation of non-
GAAP annual effective tax rate. Tax reserves were released as a result of the
expiration of statute of limitations which resulted in a discrete tax benefit
for GAAP purposes. This tax benefit is excluded from our non-GAAP annual
effective tax rate to the extent it is not related to on-going business
operations.

** Amounts may not foot due to rounding.
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
  Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)  
                                                                                
             (In thousands, except percentages and per share data)              
The Company’s U.S. GAAP results for the three months ended September 30, 2025
included special items which impacted the U.S. GAAP measures as follows:
                                                                                
                                                                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
_____________

* The Company’s non-GAAP annual effective tax rate is calculated without the tax
expense related to the valuation allowance against certain U.S. Federal and
State deferred tax assets. The valuation allowance was recorded based on an
assessment of available positive and negative evidence, including,
predominantly, an estimate that we will be in a three-year cumulative U.S. loss
position on a GAAP basis as of September 30, 2025. However, based on the same
assessment, including, predominantly, our being, in a three-year cumulative U.S.
income position on a non-GAAP basis, which excludes the impact of our non-GAAP
adjustments, we concluded that recording a valuation allowance would not have
been appropriate for non-GAAP reporting. As a result, the tax expense for the
valuation allowance was added back to our calculation of non-GAAP annual
effective tax rate.

** Amounts may not foot due to rounding
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
  Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)  
                                                                                
                       (In thousands, except percentages)                       
                                                                                
  Rec…                                                                          
  of                                                                            
  GAAP                                                                          
  rev…                                                                          
  gro…                                                                          
  to            Three                                Nine                       
  Non…          mont…                               mont…                       
  org…          ended                               ended                       
  rev…          Sept…                               Sept…                       
  gro…    2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Con…                                                                          
  GAAP    $     298,…       $     285,…       $     865,…       $     824,…     
  rev…                                                                          
  Con…                                                                          
  GAAP              5  %              8  %              5  %              7  %  
  rev…                                                                          
  gro…                                                                          
  For…                                                                          
  cur…           -231                               -8,9…                       
  imp…                                                                          
  Non…                                                                          
  org…    $     298,…       $     285,…       $     856,…       $     824,…     
  rev…                                                                          
  Non…                                                                          
  org…              5  %                                4  %                    
  rev…                                                                          
  gro…                                                                          
  Inf…                                                                          
  Sys…    $     192,…       $     173,…       $     561,…       $     507,…     
  GAAP                                                                          
  rev…                                                                          
  Inf…                                                                          
  Sys…                                                                          
  GAAP             11  %              9  %             10  %              6  %  
  rev…                                                                          
  gro…                                                                          
  For…                                                                          
  cur…            -54                               -4,6…                       
  imp…                                                                          
  Non…                                                                          
  org…    $     192,…       $     173,…       $     556,…       $     507,…     
  rev…                                                                          
  Non…                                                                          
  org…             11  %                               10  %                    
  rev…                                                                          
  gro…                                                                          
  Vit…                                                                          
  Care    $     69,5…       $     77,9…       $     215,…       $     358,…     
  GAAP                                                                          
  rev…                                                                          
  Vit…                                                                          
  Care                                                                          
  GAAP            -11  %            -53  %            -40  %            -28  %  
  rev…                                                                          
  gro…                                                                          
  MSA           -4,2…             -3,6…             -12,…             -14,…     
  Rev…                                                                          
  Non…                                                                          
  adj…          65,2…             74,2…             202,…             344,…     
  rev…                                                                          
  Non…                                                                          
  adj…            -12  %            -52  %            -41  %            -26  %  
  rev…                                                                          
  gro…                                                                          
  Les…                                                                          
  Rev…                                                                          
  from            332              -803               332             -120…     
  div…                                                                          
  bus…                                                                          
  For…                                                                          
  cur…            301                               -1,0…                       
  imp…                                                                          
  Non…                                                                          
  org…    $     65,9…       $     73,4…       $     202,…       $     223,…     
  rev…                                                                          
  Non…                                                                          
  org…            -10  %                              -10  %                    
  rev…                                                                          
  gro…                                                                          
  Tot…                                                                          
  GAAP    $     560,…       $     536,…       $     1,64…       $     1,69…     
  rev…                                                                          
  Tot…                                                                          
  GAAP              4  %             -9  %             -3  %             -4  %  
  rev…                                                                          
  gro…                                                                          
  MSA           -4,2…             -3,6…             -12,…             -14,…     
  Rev…                                                                          
  Non…                                                                          
  adj…          556,…             533,…             1,62…             1,67…     
  rev…                                                                          
  Non…                                                                          
  adj…              4  %             -8  %             -3  %             -2  %  
  rev…                                                                          
  gro…                                                                          
  Les…                                                                          
  Rev…                                                                          
  from            332              -803               332             -120…     
  div…                                                                          
  bus…                                                                          
  For…                                                                          
  cur…             16                               -14,…                       
  imp…                                                                          
  Non…                                                                          
  org…    $     556,…       $     532,…       $     1,61…       $     1,55…     
  rev…                                                                          
  Non…                                                                          
  org…              5  %                                4  %                    
  rev…                                                                          
  gro…                                                                          
                                                                                
_____________________________________________

(1) We manufacture certain products or product components in accordance with
manufacturing services agreements. We do not include the contract revenue in our
adjusted

revenue as the commercial relationship under these types of agreements are
originally negotiated contemporaneously with a business combination or other
transactions and

are not indicative of normal market transactions.

(2) For businesses divested, non-GAAP organic revenue growth excludes prior
period revenue associated with the divested business for the same length

of time they were not owned by the company in the current year. The divested
business prior period revenue in this line item does not include MSA revenue,
which is excluded on a separate line.

(3) We exclude the impact of foreign exchange rate changes to show a constant
currency comparison of our underlying business performance.
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
  Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)  
                                                                                
                                 (In thousands)                                 
                                                                                
  Reconc…                                                                       
  of Net                                                                        
  Cash                                                                          
  Provid…                                                                       
  by                                                                            
  Operat…            Three                               Nine                   
  Activi…           months                             months                   
  to Free            ended                              ended                   
  Cash             Septem…                           Septemb…                   
  Flow       2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provid…    $      99,586           56,710    $      218,645    $     119,248  
  by                                                                            
  operat…                                                                       
  activi…                                                                       
  Purcha…                                                                       
  of                                                                            
  proper…          -16,186          -29,080           -45,999          -63,397  
  plant                                                                         
  and                                                                           
  equipm…                                                                       
  Procee…                                                                       
  from                  17                —                39               42  
  sale of                                                                       
  assets                                                                        
  Free                                                                          
  cash       $      83,417    $      27,630    $      172,685    $      55,893  
  flow                                                                          
                                                                                
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
  Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)  
                                                                                
                                 (In thousands)                                 
                                                                                
                       Net Debt                                                 
  Net Leverage         As of September 30,                                      
  Ratio Calculation    2026                                                     
 ────────────────────────────────────────────────────────────────────────────── 
  Current portion      $                                           18,750       
  of long-term debt                                                             
  Long-Term Debt                                                1,133,096       
  Total GAAP                                1,151,846                           
  Long-Term Debt                                                                
  Add: Unamortized                                                              
  Debt Issuance                                 7,967                           
  Costs/Discounts(…                                                             
  Less: Cash and                             -301,780                           
  cash equivalents                                                              
  Net Debt             $                      858,033                           
  (Non-GAAP)                                                                    
  (1)Represents                                                                 
  unamortized debt                                                              
  issuance                                                                      
  costs and                                                                     
  original issue                                                                
  discounts                                                                     
  deducted from the                                                             
  carrying value of                                                             
  long-term debt on                                                             
  the Condensed                                                                 
  Consolidated                                                                  
  Balance Sheets in                                                             
  accordance with                                                               
  U.S. GAAP.                                                                    
  Management                                                                    
  adds back these                                                               
  costs to present                                                              
  total                                                                         
  contractual                                                                   
  principal                                                                     
  obligations                                                                   
  outstanding when                                                              
  evaluating debt                                                               
  leverage.                                                                     
                       TTM Adjusted EBITDA                                      
                       As of September 30,                                      
                       2026                                                     
  GAAP net income      $                                           60,332       
  Non-GAAP                                                                      
  adjustments:                                                                  
  Interest, net                                                    68,124       
  Stock                                                                         
  compensation                                                     51,623       
  expense                                                                       
  Depreciation and                                                              
  amortization                                                    200,065       
  expense                                                                       
  Restructuring,                                                                
  strategic                                                        64,826       
  transaction and                                                               
  integration                                                                   
  Settlements                                                       1,300       
  Quality system                                                                
  and                                                              30,883       
  product-related                                                               
  remediation                                                                   
  Asset write-offs                                                              
  and similar                                                         887       
  charges                                                                       
  Gain on sale of                                                  -2,240       
  business                                                                      
  Impairment of                                                                 
  equity method                                                     2,832       
  investment                                                                    
  Noncash release                                                               
  of loss on                                                       -4,436       
  contract                                                                      
  provision                                                                     
  Gross profit on                                                               
  contract                                                         -1,807       
  manufacturing                                                                 
  Tariff refunds                                                  -29,246       
  Noncash                                                                       
  impairment and                                                      766       
  other JV items                                                                
  Provision for                                                   -23,104       
  income taxes                                                                  
  Total non-GAAP                                                  360,473       
  adjustments                                                                   
  TTM Adjusted         $                                          420,805       
  EBITDA                                                                        
                                                       Net Leverage Ratio       
  Net Debt             $                                          858,033       
  Divided by: TTM      $                                          420,805       
  Adjusted EBITDA                                                               
  Net Leverage                                                       2.04    x  
  Ratio                                                                         
                                                                                
                                                                                
                       ICU MEDICAL, INC. AND SUBSIDIARIES                       
                                                                                
                                                                                
                                Fiscal Year 2026                                
                                                                                
                                                                                
                              Outlook (Unaudited)                               
                                                                                
                      (In millions, except per share data)                      
                                                                                
                      Low End of                    High End of                 
                      Guidance                      Guidance                    
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP net income     $                       73    $                       83  
  Non-GAAP                                                                      
  adjustments:                                                                  
  Interest, net                               65                            65  
  Stock                                                                         
  compensation                                50                            50  
  expense                                                                       
  Depreciation and                                                              
  amortization                               203                           203  
  expense                                                                       
  Restructuring,                                                                
  strategic                                   52                            52  
  transaction and                                                               
  integration                                                                   
  Quality and                                                                   
  regulatory                                  25                            25  
  initiatives and                                                               
  remediation                                                                   
  Noncash release                                                               
  of loss on                                  -4                            -4  
  contract                                                                      
  provision                                                                     
  Gross profit on                                                               
  contract                                    -2                            -2  
  manufacturing                                                                 
  Tariff refunds                             -19                           -19  
  Benefit for                                -28                           -18  
  income taxes                                                                  
  Total non-GAAP      $                      342    $                      352  
  adjustments                                                                   
  Adjusted EBITDA     $                      415    $                      435  
  GAAP income per     $                     2.89    $                     3.29  
  share                                                                         
  Non-GAAP                                                                      
  adjustments:                                                                  
  Stock                                                                         
  compensation                              1.98                          1.98  
  expense                                                                       
  Amortization                              5.28                          5.28  
  expense                                                                       
  Restructuring,                                                                
  strategic                                 2.06                          2.06  
  transaction and                                                               
  integration                                                                   
  Quality and                                                                   
  regulatory                                0.99                          0.99  
  initiatives and                                                               
  remediation                                                                   
  Noncash release                                                               
  of loss on                               -0.12                         -0.12  
  contract                                                                      
  provision                                                                     
  Gross profit on                                                               
  contract                                 -0.08                         -0.08  
  manufacturing                                                                 
  Tariff refunds                           -0.79                         -0.79  
  Tax benefit from                                                              
  discrete reserve                                                              
  release and                              -1.33                         -1.33  
  valuation                                                                     
  allowance                                                                     
  Estimated income                                                              
  tax impact from                          -2.28                         -2.28  
  adjustments                                                                   
  Adjusted                                                                      
  earnings per        $                     8.60    $                     9.00  
  share                                                                         
                                                                                
CONTACT:

ICU Medical, Inc.

Brian Bonnell, Chief Financial Officer

(949) 366-2183

ICR, Inc.

John Mills, Partner

(646) 277-1254

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.